Comparative efficacy and safety of the non–vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation
K Senoo, GYH Lip - Seminars in Thrombosis and Hemostasis, 2015 - thieme-connect.com
The non–vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor
(dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have …
(dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have …
Comparison of anticoagulant therapy for atrial fibrillation-novel oral anticoagulants versus vitamin K antagonists
In patients with non-valvular atrial fibrillation (NVAF), oral anticoagulation is important for
prevention of stroke and systemic embolism (SE). While Vitamin K antagonists (VKAs) have …
prevention of stroke and systemic embolism (SE). While Vitamin K antagonists (VKAs) have …
Use of non-vitamin K antagonist oral anticoagulants in special patient populations with nonvalvular atrial fibrillation: a review of the literature and application to clinical …
J Kalabalik, GB Rattinger, J Sullivan, M Slugocki… - Drugs, 2015 - Springer
Atrial fibrillation is a commonly encountered arrhythmia associated with increased risk for
thromboembolic events. Anticoagulation is necessary to decrease the risk of ischemic …
thromboembolic events. Anticoagulation is necessary to decrease the risk of ischemic …
Direct oral anticoagulants in nonvalvular atrial fibrillation: practical considerations on the choice of agent and dosing
D Farmakis, P Davlouros, G Giamouzis… - Cardiology, 2018 - karger.com
Direct or new oral anticoagulants (NOACs), including the direct thrombin inhibitor dabigatran
and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, have recently …
and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, have recently …
[HTML][HTML] The nonvitamin K antagonist oral anticoagulants and atrial fibrillation: challenges and considerations
A Plitt, S Bansilal - Journal of atrial fibrillation, 2017 - ncbi.nlm.nih.gov
Purpose The nonvitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban,
apixaban, and edoxaban are used for the reduction of the risk of stroke or systemic …
apixaban, and edoxaban are used for the reduction of the risk of stroke or systemic …
Non–vitamin K antagonist oral anticoagulants in the treatment of atrial fibrillation
AC Fanaroff, EM Ohman - Annual review of medicine, 2019 - annualreviews.org
Atrial fibrillation (AF) increases a patient's stroke risk four-to five-fold. Anticoagulation with
the vitamin K antagonist (VKA) warfarin reduces the risk of stroke by 67%, but warfarin …
the vitamin K antagonist (VKA) warfarin reduces the risk of stroke by 67%, but warfarin …
Clinical significance of non-vitamin K antagonist oral anticoagulants in the management of atrial fibrillation
Atrial fibrillation (AF) is the most commonly observed rhythm disorder in clinical practice. It is
associated with a high risk of thromboembolic stroke and increased cardiovascular mortality …
associated with a high risk of thromboembolic stroke and increased cardiovascular mortality …
Efficacy of new oral anticoagulants in patients with atrial fibrillation previously treated with warfarin: A meta-analysis of randomized controlled trials
L Fauchier, N Clementy… - International …, 2014 - internationaljournalofcardiology.com
Vitamin K antagonists (VKAs), together with newer oral anticoagulants (NOACs) such as
dabigatran, rivaroxaban, or apixaban, reduce the risk of stroke in patients with atrial …
dabigatran, rivaroxaban, or apixaban, reduce the risk of stroke in patients with atrial …
Practical considerations for the nonvitamin K antagonist oral anticoagulants
R Trikha, PR Kowey - Cardiology, 2017 - karger.com
Abstract Objectives: Dabigatran, rivaroxaban, apixaban, and edoxaban are nonvitamin K
antagonist oral anticoagulants (NOACs) approved for stroke prevention in patients with …
antagonist oral anticoagulants (NOACs) approved for stroke prevention in patients with …
Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach
P Verdecchia, F Angeli, C Bartolini… - Expert Opinion on …, 2015 - Taylor & Francis
Introduction: Choosing between different non-vitamin K antagonist oral anticoagulants
(NOACs) in non-valvular atrial fibrillation (NVAF) is difficult due to the absence of head to …
(NOACs) in non-valvular atrial fibrillation (NVAF) is difficult due to the absence of head to …